Importantly, ISR activation correlated with tumor progression and suppression of T cell function, effects that could be reversed by combined blockade of PD-1, TIGIT, and ISR inhibition in the CMT167 mouse lung cancer model [158]. Here, PDCD1 is linked to lung carcinoma.